戊聚糖多硫酸钠长期使用与黄斑疾病的关联:来自美国队列的发现
基于美国大型医疗索赔数据库2002至2016年的回顾性匹配队列研究,比较戊聚糖多硫酸钠(PPS)使用者与匹配对照者。5年随访时多因素分析无显著关联,7年随访时PPS使用者发生非典型黄斑病变+年龄相关性黄斑变性(AMD)结局的比值比显著升高(OR=1.41,95%CI 1.09至1.83,p=0.009)。
要点
- 7年随访时PPS使用者非典型黄斑病变+AMD结局风险升高(OR=1.41,95%CI 1.09至1.83)。
- 5年随访时多因素分析未显示PPS使用与黄斑疾病显著关联(p>0.13)。
- 7年时非典型黄斑病变结局:PPS组10例(0.6%)vs 对照组25例(0.3%)。
核心结论
- 在大型全国性队列的7年随访中,PPS暴露与新发黄斑疾病诊断相关。
研究设计与样本
- 回顾性匹配队列研究,使用美国大型医疗索赔数据库2002至2016年数据。
- 5年比较3012例PPS使用者与15060例匹配对照,7年比较1604例PPS使用者与8017例匹配对照。
主要发现
- 5年随访时,9例(0.3%)PPS使用者进展为非典型黄斑病变结局,对照组32例(0.2%)。
- 7年随访时,10例(0.6%)PPS使用者进展为非典型黄斑病变结局,对照组25例(0.3%)。
- 5年随访时,103例(3.4%)PPS使用者发生非典型黄斑病变+AMD结局,对照组440例(2.9%)。
- 7年随访时,87例(5.4%)PPS使用者发生非典型黄斑病变+AMD结局,对照组328例(4.1%)。
- 5年时多因素分析无显著关联(p>0.13);7年时PPS使用者非典型黄斑病变+AMD结局的OR=1.41(95%CI 1.09至1.83,p=0.009)。
关键数值与推荐
- 主要结局包括新诊断的遗传性或继发性色素性黄斑病变(非典型黄斑病变结局)。
- 主要结局还包括新诊断的干性年龄相关性黄斑变性或玻璃膜疣(非典型黄斑病变+AMD结局)。
- 7年时非典型黄斑病变+AMD结局的OR=1.41(95%CI 1.09至1.83,p=0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: A series at a single clinical centre recently demonstrated an association between the interstitial cystitis drug pentosan polysulfate sodium (PPS) and a vision-threatening pigmentary maculopathy. The aim of this study was to determine if an association exists between PPS use and macular disease in a large national cohort. METHODS: A retrospective, matched cohort study using data from a large US medical claims database from 2002 to 2016 was performed. A total of 3012 and 1604 PPS users were compared with 15 060 and 8017 matched controls at 5 and 7 years, respectively. The primary outcome measures included (1) any new diagnosis of a hereditary or secondary pigmentary maculopathy (atypical maculopathy outcome), and (2) any new diagnosis of dry age-related macular degeneration (AMD) or drusen in addition to the aforementioned diagnoses (atypical maculopathy+AMD outcome). RESULTS: At the 5-year and 7-year follow-up, 9 (0.3%) and 10 (0.6%) PPS patients progressed to the atypical maculopathy outcome compared with 32 (0.2%) and 25 (0.3%) control patients, respectively. 103 (3.4%) and 87 (5.4%) PPS patients developed the atypical maculopathy+AMD outcome compared with 440 (2.9%) and 328 (4.1%) control patients at 5 and 7 years, respectively. At 5 years, multivariate analysis showed no significant association (p>0.13). At 7 years, PPS users had significantly increased odds of having the atypical maculopathy+AMD outcome (OR=1.41, 95% CI 1.09 to 1.83, p=0.009). CONCLUSIONS: PPS exposure was associated with a new diagnosis of macular disease at the 7-year follow-up in a large national cohort.
引用
- Jain N, Li AL, Yu Y, et al. Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. Br J Ophthalmol. 2019. PMID: 31694837. doi:10.1136/bjophthalmol-2019-314765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。